BCAX (Bicara Therapeutics) Debt-to-Revenue : N/A (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Bicara Therapeutics Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Bicara Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.61 Mil. Bicara Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.13 Mil. Bicara Therapeutics's annualized Revenue for the quarter that ended in Dec. 2024 was $0.00 Mil.

Bicara Therapeutics Debt-to-Revenue Historical Data

The historical data trend for Bicara Therapeutics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bicara Therapeutics Debt-to-Revenue Chart

Bicara Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Debt-to-Revenue

N/A

Bicara Therapeutics Quarterly Data
	Dec22	Sep23	Dec23	Jun24	Sep24	Dec24
Debt-to-Revenue	Get a 7-Day Free Trial			N/A	N/A	N/A	N/A	N/A

Competitive Comparison of Bicara Therapeutics's Debt-to-Revenue

For the Biotechnology subindustry, Bicara Therapeutics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bicara Therapeutics's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bicara Therapeutics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Bicara Therapeutics's Debt-to-Revenue falls into.

Save Embed

;

Save Embed

;

Bicara Therapeutics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Bicara Therapeutics's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.607	+	0.131)	/	N/A
	=	N/A

Bicara Therapeutics's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.607	+	0.131)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.

Bicara Therapeutics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Bicara Therapeutics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Bicara Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicara Therapeutics Inc (NAS:BCAX) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116

Website

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.